Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment algorithms for nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Some patients with mCRPC are receiving triple combinations of current therapies. The dynamic late-phase pipeline mostly focuses on mCRPC and comprises a plethora of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, Roche’s ipatasertib, AstraZeneca’s capivasertib) and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s 177Lu-PSMA-617, Telix’s 77Lu-DOTA-rosopatamab, POINT Biopharma’s 177Lu-PNT2002). These agents will likely contribute to robust market growth over the 2021-2031 forecast period.
QUESTIONS ANSWERED
What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
What are the key drivers and constraints in the prostate cancer therapy market, and how will the major markets evolve over the 10-year forecast period?
What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
What is the clinical and commercial potential of late-phase pipeline products, and what will their positioning and uptake in the market be?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Major-market share of prostate cancer drug classes: 2021
Major-market sales of prostate cancer drug classes: 2031
Drug-treatable population share and major-market sales share: 2021
Drug-treatable population share and major-market sales share: 2031
Population positioning of therapies in prostate cancer
Prostate cancer SWOT analysis
Market drivers and constraints
What factors are driving the market for prostate cancer?
What factors are constraining the market for prostate cancer?
Major-market sales of key agents for prostate cancer: 2021-2031
Major-market sales for prostate cancer by region: 2021, 2026, and 2031
Major-market sales for prostate cancer by drug class: 2021-2031
Segment-specific trends
Major-market share of key agents for metastatic hormone-sensitive prostate cancer: 2031
Patient-share dynamics of key agents for newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer in the United States: 2021-2031
Patient-share dynamics of key agents for biochemically recurrent hormone-sensitive prostate cancer in the United States: 2021-2031
Patient-share dynamics of key agents for metastatic hormone-sensitive prostate cancer in the United States: 2021-2031
Patient-share dynamics of key hormonal agents for nonmetastatic castrate-resistant prostate cancer in the United States: 2021-2031
Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in France: 2021-2031
Share of major-market sales in first-line metastatic castrate-resistant prostate cancer by agent: 2031
Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in France: 2021-2031
Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in France: 2021-2031
Share of major-market sales in second- and subsequent-line metastatic castrate-resistant prostate cancer by drug class: 2031
Forecast
Market forecast assumptions
Market forecast dashboard
Etiology and pathophysiology
Key findings
Disease overview
Disease pathophysiology
Biology and metastatic spread of prostate cancer
Development of castrate-resistant prostate cancer
Molecular alterations involved in castrate-resistant prostate cancer
Prostate-specific antigen
Key clinical uses of prostate-specific antigen as a biomarker in prostate cancer
Staging classification and grading systems for prostate cancer
TNM staging classification system for prostate cancer
Classification of level of risk of recurrence of prostate cancer
Key pathways and drug targets
Androgen receptor-signaling pathway
Androgen-mediated growth of normal and cancerous prostate cells
Splice variants of the androgen receptor
Emerging drug targets in prostate cancer
PARP inhibition: mechanism of action
Immune checkpoint inhibitors and modulators
Anatomic location and architecture of the prostate gland
Epidemiology
Key findings
Key updates
Epidemiology populations
Disease definition
Methods
Sources used for diagnosed incidence of prostate cancer
Number of diagnosed incident cases of prostate cancer in the major pharmaceutical markets: 2021-2031
Disease definition
Methods
Sources used for TNM stage and NCCN risk categories of prostate cancer
Diagnosed incident cases of prostate cancer in the major pharmaceutical markets by TNM stage and NCCN risk category: 2021-2031
Disease definition
Methods
Sources used for recurrent incidence of prostate cancer
Number of biochemically and metastatic recurrent incident cases of prostate cancer in the major pharmaceutical markets: 2021-2031
Sources used for drug-treatable prostate cancer population
Drug-treatable cases of prostate cancer in the major pharmaceutical markets: 2021-2031
Prostate cancer patient-flow model
Sources used for prostate cancer drug-treated population
Drug-treated cases of prostate cancer in the major pharmaceutical markets: 2021-2031
Current treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for prostate cancer
Key current therapies
Overview
Mechanism of action of key current drug classes used for prostate cancer
Current treatments used for prostate cancer
Market events impacting the use of key current therapies for prostate cancer
Advantages and disadvantages of Zytiga
Key results from clinical trials investigating Zytiga for the treatment of prostate cancer
Ongoing clinical development of Zytiga
Key ongoing clinical trials of Zytiga in the treatment of prostate cancer
Expert insight: Zytiga
Advantages and disadvantages of Xtandi
Key results from clinical trials investigating Xtandi for the treatment of prostate cancer
Ongoing clinical development of Xtandi
Key ongoing clinical trials of Xtandi in the treatment of prostate cancer
Expert insight: Xtandi
Key results from select clinical trials investigating Erleada for the treatment of prostate cancer
Ongoing clinical development of Erleada
Expert insight: Erleada
Key results from select clinical trials investigating Nubeqa for the treatment of prostate cancer
Ongoing clinical development of Nubeqa
Key ongoing clinical trials of Nubeqa in the treatment of prostate cancer
Expert insight: Nubeqa
Key results from select clinical trials investigating Yonsa for the treatment of prostate cancer
Expert insight: Yonsa
Advantages and disadvantages of LHRH agonists / antagonists
Expert insight: LHRH agonists / antagonists
Key results from select clinical trials investigating Orgovyx for the treatment of prostate cancer
Ongoing clinical development of Orgovyx
Expert insight: Orgovyx
Key results from select clinical trials investigating Pluvicto for the treatment of prostate cancer
Ongoing clinical development of Pluvicto
Key ongoing clinical trials of Pluvicto in the treatment of prostate cancer
Expert insight: Pluvicto
Advantages and disadvantages of Provenge
Key results from clinical trials investigating Provenge for the treatment of prostate cancer
Ongoing clinical development of Provenge
Key ongoing clinical trials investigating Provenge in the treatment of prostate cancer
Expert insight: Provenge
Advantages and disadvantages of Xofigo
Key results from clinical trials investigating Xofigo for the treatment of prostate cancer
Ongoing clinical development of Xofigo
Key ongoing clinical trials of Xofigo in the treatment of prostate cancer
Expert insight: Xofigo
Advantages and disadvantages of Jevtana
Key results from clinical trials investigating Jevtana for the treatment of prostate cancer
Ongoing clinical development of Jevtana
Expert insight: Jevtana
Advantages and disadvantages of docetaxel
Key results from clinical trials investigating docetaxel for the treatment of prostate cancer
Expert insight: docetaxel
Key results from select clinical trials investigating Lynparza for the treatment of prostate cancer
Ongoing clinical development of Lynparza
Key ongoing clinical trials of Lynparza in the treatment of prostate cancer
Expert insight: Lynparza
Key results from clinical trials investigating Rubraca for the treatment of prostate cancer
Ongoing clinical development of Rubraca
Key ongoing clinical trials of Rubraca in the treatment of prostate cancer
Expert insight: Rubraca
Medical practice
Newly diagnosed low- and intermediate-risk hormone-sensitive prostate cancer
Newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer
Metastatic hormone-sensitive prostate cancer
Biochemically recurrent prostate cancer
Nonmetastatic castrate-resistant prostate cancer
First-line metastatic castrate-resistant prostate cancer
Second- and subsequent-line metastatic castrate-resistant prostate cancer
Patient characteristics influencing drug selection in prostate cancer
Treatment decision tree for low- and intermediate-risk prostate cancer: major markets
Treatment decision tree for high-risk and N1M0 prostate cancer: major markets
Treatment decision tree for nonmetastatic castrate-resistant prostate cancer: United States
Treatment decision tree for metastatic hormone-sensitive prostate cancer: United States
Treatment decision tree for metastatic castrate-resistant prostate cancer: major markets
Unmet need overview
Current and future attainment of unmet needs in prostate cancer
Top unmet needs in prostate cancer: current and future attainment
Expert insight: unmet need in prostate cancer
Drug pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging therapies
Key findings
Key emerging therapies
Key therapies in development for prostate cancer
Estimated market authorization dates of key emerging therapies for the treatment of prostate cancer
Key results from select clinical trials investigating CAN-2409 for the treatment of prostate cancer
Analysis of clinical development program for CAN-2409
Key ongoing clinical trials of CAN-2409 in the treatment of prostate cancer
Expert insight: CAN-2409
Expectations for market authorization and sales opportunity of CAN-2409 in prostate cancer
Key results from clinical trials investigating Keytruda for the treatment of prostate cancer
Analysis of clinical development program for Keytruda
Key ongoing clinical trials of Keytruda in the treatment of prostate cancer
Expert insight: Keytruda
Expectations for market authorization and sales opportunity of Keytruda in prostate cancer
Key results from clinical trials investigating Opdivo for the treatment of prostate cancer
Analysis of clinical development program for Opdivo
Key ongoing clinical trials of Opdivo in the treatment of prostate cancer
Expert insight: Opdivo
Expectations for market authorization and sales opportunity of Opdivo in prostate cancer
Key results from clinical trials investigating Talzenna for the treatment of prostate cancer
Analysis of clinical development program for Talzenna
Key ongoing clinical trials of Talzenna in the treatment of prostate cancer
Expert insight: Talzenna
Expectations for market authorization and sales opportunity of Talzenna in prostate cancer
Key results from clinical trials investigating Zejula for the treatment of prostate cancer
Analysis of clinical development program for Zejula
Key ongoing clinical trials of Zejula in the treatment of prostate cancer
Expert insight: Zejula
Expectations for launch and sales opportunity of Zejula in prostate cancer
Key results from select clinical trials investigating ipatasertib for the treatment of prostate cancer
Analysis of clinical development program for ipatasertib
Expert insight: ipatasertib
Expectations for market authorization and sales opportunity of ipatasertib in prostate cancer
Key results from select clinical trials investigating capivasertib for the treatment of prostate cancer
Analysis of clinical development program for capivasertib
Key ongoing clinical trials of capivasertib in the treatment of prostate cancer
Expert insight: capivasertib
Expectation for market authorization and sales opportunity of capivasertib in prostate cancer
Key results from select clinical trials investigating 177Lu-DOTA-rosopatamab for the treatment of prostate cancer
Analysis of the clinical development program for 177Lu-DOTA-rosopatamab
Key ongoing clinical trials of 177Lu-DOTA-rosopatamab in the treatment of prostate cancer
Expert insight: 177Lu-DOTA-rosopatamab
Expectations for market authorization and sales opportunity of 177Lu-DOTA-rosopatamab in prostate cancer
Key results from select clinical trials investigating 177Lu-PNT2002 for the treatment of prostate cancer
Analysis of the clinical development program for 177Lu-PNT2002
Key ongoing clinical trials of 177Lu-PNT2002 in the treatment of prostate cancer
Expert insight: 177Lu-PNT2002
Expectations for market authorization and sales opportunity of 177Lu-PNT2002 in prostate cancer
Analysis of the clinical development program for 177Lu-PSMA-I&T
Key ongoing clinical trials of 177Lu-PSMA-I&T in the treatment of prostate cancer
Expert insight: 177Lu-PSMA-I&T
Expectations for market authorization and sales opportunity of 177Lu-PSMA-I&T in prostate cancer
Key results from select clinical trials investigating sabizabulin (VERU-111) for the treatment of prostate cancer
Analysis of the clinical development program for sabizabulin (VERU-111)
Key ongoing clinical trials of sabizabulin (VERU-111) in the treatment of prostate cancer
Expert insight: sabizabulin (VERU-111)
Expectations for market authorization and sales opportunity of sabizabulin (VERU-111) in prostate cancer
Key results from select clinical trials investigating Cabometyx for the treatment of prostate cancer
Analysis of clinical development program for Cabometyx
Key ongoing clinical trials of Cabometyx in the treatment of prostate cancer
Expert insight: Cabometyx
Expectations for market authorization and sales opportunity of Cabometyx in prostate cancer
Analysis of the clinical development program for Verzenio / Verzenios
Key ongoing clinical trials of Verzenio / Verzenios in the treatment of prostate cancer
Expert insight: Verzenio / Verzenios
Expectations for market authorization and sales opportunity of Verzenio / Verzenios in prostate cancer
Key results from clinical trials investigating vobramitamab duocarmazine for the treatment of prostate cancer
Analysis of the clinical development program for vobramitamab duocarmazine
Key ongoing clinical trials of vobramitamab duocarmazine in the treatment of prostate cancer
Expectations for market authorization and sales opportunity of vobramitamab duocarmazine in prostate cancer
Early-phase pipeline analysis
Select compounds in early-phase development for prostate cancer
Access and reimbursement overview
Region-specific reimbursement practices
Key market access considerations in prostate cancer: United States
General reimbursement environment: United States
Key market access considerations in prostate cancer: EU5
General reimbursement environment: EU5
Key market access considerations in prostate cancer: Japan
General reimbursement environment: Japan
Appendix
Abbreviations
Brands, Marketers, and Generic Availability of Current Therapies Used for Prostate Cancer by Market
Prostate cancer bibliography
Saurabh Virdi
Saurabh Virdi, B.Tech.,Lead Healthcare Research & Data Analyst, Oncology. Mr. Virdi has more than seven years working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, HIV, vaccines, specialty pharma, and rare diseases. Prior to joining Clarivate, he was an assistant project manager at DelveInsight Business Research LLP, where he was responsible for developing and delivering customized market and asset value forecasts. Before DelveInsight, he worked at WNS GSK Knowledge center and SmartAnalyst, where, as part of multifunctional teams, he helped clients’ decision making throughout the development journey from early-stage to marketed drugs. He obtained his bachelor’s degree in biotechnology from Delhi Technological University in India.
Narendra Parihar
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.